Center for Drug Policy and Technology Assessment (CDPTA)

Center for Drug Policy and Technology Assessment (CDPTA)

Informed Decisions………. Better Health Outcomes

The Center for Drug Policy and Technology Assessment (CDPTA) is a pioneering regional center providing hospital-based health technology assessment (HB-HTA) services, drug information, and pharmacovigilance services. CDPTA specializes in conducting economic evaluation assessments and Decision Analytical Modeling (DAM).

Meanwhile, Health Technology Assessment (HTA) is a “multidisciplinary process that uses explicit methods to determine the value of health technology at different points in its lifecycle. It aims to inform decision-making and promote an equitable, efficient, high-quality health system”. 

The CDPTA generates (HB-HTA) reports which include an assessment of the clinical effectiveness/ efficacy evidence, safety evidence, quality of life evidence, and economic evidence.

CDPTA Mission

To improve a rational selection and use of health technologies through applying HTA to generate evidence-based information to policymakers, health care providers, and patients, and maintain HTA capacity building within the Center. 

CDPTA Vision

To become a leading regional center providing HTA and drug information services recommendations to improve health outcomes.

CDPTA Core Values

  • Integrity
  • Teamwork
  • Passion
  • Continuous learning
  • Innovation and creativity 

Health Technology Assessment Fellowship Program (HTA-FB) 

The HTA Fellowship Program (HTA-FP) aims to build capacities for conducting health technology assessments and health economics. The program provides fellows with individualized post-graduate training to become independent HTA researchers.

For further information about HTA-FP, please refer to the published article entitled: “A capacity-building programme in health technology assessment for hospital pharmacists in a low- to middle-income country”.

CDPTA Team 

  • Abeer A. Al-Rabayah, BSc Pharm, MBA, MSc (iHTA), PMP, Head, Center for Drug Policy and Technology Assessment
  • Rawan F. Alfroukh, Pharm.D, BCPS, MSc (Health Econ)
  • Razan Sawalha, BS Pharm, MSc (Health Econ)
  • Maha Dalbah, Pharm.D. BCOP 
  • Khader Habash, Pharm.D